{"id":"NCT01558271","sponsor":"Eli Lilly and Company","briefTitle":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","officialTitle":"A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-10","completion":"2014-05","firstPosted":"2012-03-20","resultsPosted":"2014-10-30","lastUpdate":"2015-05-22"},"enrollment":492,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"LY2189265","otherNames":["Dulaglutide"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Liraglutide","otherNames":[]}],"arms":[{"label":"LY2189265","type":"EXPERIMENTAL"},{"label":"Placebo/LY2189265","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 in participants with type 2 diabetes mellitus who are not taking oral antidiabetic medication.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","timeFrame":"Baseline, 26 weeks","effectByArm":[{"arm":"LY2189265","deltaMin":-1.43,"sd":0.05},{"arm":"Placebo","deltaMin":0.14,"sd":0.1},{"arm":"Liraglutide","deltaMin":-1.33,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.248"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":14,"countries":["Japan"]},"refs":{"pmids":["29264713","28606095"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":280},"commonTop":["Nasopharyngitis","Constipation","Diarrhoea","Nausea","Abdominal distension"]}}